Novavax (NASDAQ:NVAX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at B. Riley Financial in a note issued to investors on Friday, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $18.00. B. Riley Financial‘s price objective would suggest a potential upside of 48.42% from the stock’s current price.
NVAX has been the topic of several other reports. Zacks Research lowered Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d)” rating on shares of Novavax in a research note on Monday, November 2nd. Citigroup reissued a “sell” rating and set a $8.00 price objective (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Wall Street Zen raised Novavax from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Novavax in a research note on Tuesday, October 27th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $12.33.
Read Our Latest Analysis on NVAX
Novavax Price Performance
NASDAQ:NVAX opened at $10.78 on Friday. Novavax has a fifty-two week low of $6.20 and a fifty-two week high of $13.39. The stock’s 50-day moving average is $10.56 and its two-hundred day moving average is $9.35. The stock has a market cap of $1.78 billion, a PE ratio of -23.43 and a beta of 2.65.
Novavax (NASDAQ:NVAX – Get Free Report) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.16. Novavax had a negative return on equity of 14.82% and a negative net margin of 18.64%. The company had revenue of $68.30 million for the quarter, compared to the consensus estimate of $50.42 million. During the same quarter in the prior year, the company earned ($1.25) EPS. The firm’s quarterly revenue was down 3.0% on a year-over-year basis. On average, equities research analysts anticipate that Novavax will post -0.38 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in shares of Novavax in the 2nd quarter worth about $8,004,000. Edgestream Partners L.P. bought a new position in Novavax during the 1st quarter valued at about $4,234,000. Renaissance Technologies LLC bought a new position in Novavax during the 1st quarter valued at about $4,049,000. Squarepoint Ops LLC bought a new position in Novavax during the 2nd quarter valued at about $1,258,000. Finally, First Trust Advisors LP lifted its holdings in Novavax by 37.7% during the 1st quarter. First Trust Advisors LP now owns 409,328 shares of the biopharmaceutical company’s stock valued at $3,332,000 after purchasing an additional 112,009 shares during the last quarter. Institutional investors own 53.04% of the company’s stock.
Novavax News Summary
Here are the key news stories impacting Novavax this week:
- Positive Sentiment: Novavax reported a Q3 loss of $0.19 per share, narrower than analysts’ expected $0.35 loss, while revenue of $68.3 million topped estimates of about $50.4 million. The loss also improved from $0.62 per share a year earlier. Article: Novavax Reports Q3 Loss, Tops Revenue Estimates
- Positive Sentiment: The company raised its 2026 revenue outlook to $385 million–$415 million, or $400 million at the midpoint—about $145 million higher than its prior framework. A $125 million milestone from Sanofi, earned after a Phase 3 trial launch, accounts for much of the increase. Novavax also reduced operating expenses and said its cash runway extends into 2029. Article: Novavax boosts 2026 revenue forecast as licensing deals pay off
- Neutral Sentiment: B. Riley reaffirmed its Buy rating, though it lowered its price target to $16 from $18. The reduced target tempers the otherwise positive analyst stance. Article: B. Riley stock recommendations
- Negative Sentiment: Investors may be focused on Novavax pushing its profitability target out to 2029. Q3 revenue was still down 3% year over year, and the higher 2026 outlook depends substantially on the Sanofi milestone, raising questions about the durability of revenue growth. Article: Novavax pushes profitability target to 2029, shares dip
Novavax Company Profile
Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.
Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.
Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.
Further Reading
- Five stocks we like better than Novavax
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
